15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Silence Therapeutics PLC, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $35.00 to $75.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $55.00 sits 376% above the current $11.55. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Silence Therapeutics PLC.
As of Jul, 3 of 3 firms rate SLN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SLN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.10 – $-0.10 · 1 analysts · -33% YoY
Next period, 1 analysts expect Silence Therapeutics PLC to earn $-0.10 a share (range $-0.10 – $-0.10), versus $-0.15 a year earlier. Full-year consensus is $-0.40, growing to $-0.39 the year after.
REVENUE · NEXT QUARTER
$849.1K
Range $0 – $4.5M · 1 analysts · +600% YoY
Revenue is expected to reach $849.1K (range $0 – $4.5M), +599.9% year-over-year. Full-year consensus is $2.5M, rising to $3.4M next year.
Top analysts covering Silence Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SLN.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$27.00+133.8% to target
Overall win rate
41%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$75.00+549.4% to target
Overall win rate
35%
+ Follow
#3
MU
Michael Ulz
Morgan Stanley
Buy
$25.00+116.5% to target
Coverage
—
+ Follow
#4
RL
Richard Law
Goldman Sachs
Sell
$3.00-74.0% to target
Coverage
—
+ Follow
#5
RL
Richard Law CFA
Goldman Sachs
Sell
$4.00-65.4% to target
Coverage
—
+ Follow
SLN stock forecast FAQ
What is SLN's average 12-month price target?+
The 2 analysts with a live target average $55.00 for Silence Therapeutics PLC over the next 12 months, ranging from a $75.00 high to a $35.00 low.
Is SLN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SLN?+
The Street-high target is $75.00 (HC Wainwright & Co.), and the Street-low is $35.00 (Chardan Capital). The average of all 2 active targets is $55.00.
How many Wall Street analysts cover SLN?+
3 analysts have an active rating on Silence Therapeutics PLC, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering SLN?+
Among analysts who currently cover SLN, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $27.00 target.
What is Silence Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.10 – $-0.10) across 1 analysts. Full-year EPS is projected at $-0.40, rising to $-0.39 the following year.
How much revenue is Silence Therapeutics PLC expected to report next quarter?+
Consensus revenue is $849.1K (range $0 – $4.5M). Full-year revenue is projected at $2.5M, growing to $3.4M next year.
Have analysts been upgrading or downgrading SLN lately?+
As of Jul, 3 of 3 firms rate SLN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SLN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
